Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RGTI | 8-K | bullish | 7/10 | Rigetti Computing's subsidiary signed a definitive $100M CHIPS Act award agreement with the U.S. Department of Commerce | Sep 9, 2026 |
| TRSO | 8-K | neutral | 4/10 | TRSO entered a non-binding letter of intent to acquire 51% of Zhongke Haichuang, a Douyin Pay ecosystem service provider | Sep 9, 2026 |
| TNXP | 8-K | neutral | 2/10 | Tonix Pharmaceuticals promoted Thomas Englese from EVP of Commercial Operations to Chief Commercial Officer, effective i | Sep 9, 2026 |
| XFOR | 8-K | bullish | 6/10 | X4 Pharmaceuticals announced a positive FDA Type C meeting outcome for its 4WARD Phase 3 chronic neutropenia trial. The | Sep 9, 2026 |
| KURA | 8-K | neutral | 2/10 | Kura Oncology appointed Jennifer Fulk as CFO, replacing Troy E. Wilson and Thomas Doyle in those roles, effective Septem | Sep 9, 2026 |
| KPRX | 8-K | neutral | 3/10 | Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affa | Sep 9, 2026 |
| ONEW | 8-K | neutral | 2/10 | Director Jeffrey B. Lamkin resigned from the board and audit committee effective September 3, 2026, with the board reduc | Sep 9, 2026 |
| VWAV | 8-K | neutral | 2/10 | VisionWave Holdings furnished an updated corporate overview investor presentation on September 7, 2026, under Item 7.01 | Sep 9, 2026 |
| QBTS | 8-K | bullish | 7/10 | D-Wave Quantum Inc. finalized a definitive Other Transaction Agreement (OTA) with the U.S. Department of Commerce for up | Sep 9, 2026 |
| AVR | 8-K | neutral | 3/10 | Anteris Technologies appointed Brent Moen as CFO effective September 11, 2026, replacing Matthew McDonnell who transitio | Sep 9, 2026 |
| NVA | 8-K | neutral | 4/10 | Nova Minerals Corp announced the arrival of ~500 tons of processing and refining equipment in Port MacKenzie, Alaska, fo | Sep 9, 2026 |
| IART | 8-K | neutral | 4/10 | Integra LifeSciences filed an 8-K furnishing an updated investor presentation for use in connection with its previously- | Sep 9, 2026 |
| KOS | 8-K | neutral | 3/10 | Kosmos Energy announced a partial redemption of $25 million of its 7.750% senior notes due 2027, set to close on Septemb | Sep 9, 2026 |
| SLNH | 8-K | bullish | 6/10 | Soluna Holdings announced completion of its 83 MW Project Kati 1 in Texas, energizing the final 14 MW on time and liftin | Sep 9, 2026 |
| UCB | 8-K | mixed | 7/10 | United Community Banks completed a strategic balance sheet repositioning, selling $2.6B in low-yielding securities (2.20 | Sep 9, 2026 |
| PYXS | 8-K | neutral | 3/10 | Pyxis Oncology appointed interim CEO Thomas Civik as permanent CEO and Chairman, replacing John Flavin who becomes Lead | Sep 9, 2026 |
| PM | 8-K | bullish | 5/10 | Philip Morris International raised its 2026 full-year adjusted diluted EPS forecast to $8.35-$8.50, representing 10.7%-1 | Sep 9, 2026 |
| ENGN | 8-K | neutral | 5/10 | enGene reported Q3 2026 results with a net loss of $0.47 per share, which was a 17.5% beat vs the $-0.48 consensus, but | Sep 9, 2026 |
| NBR | 8-K | neutral | 4/10 | Nabors Industries published an investor presentation reiterating its Q3 and full-year 2026 outlook, highlighting a $100M | Sep 9, 2026 |
| IONQ | 8-K | bullish | 7/10 | IonQ issued a press release raising its full-year 2026 revenue guidance to $450M-$460M, following its acquisition of Sky | Sep 9, 2026 |
| GPI | 8-K | mixed | 6/10 | Group 1 Automotive announced a $1.25B senior notes offering to fund the pending Hennessy Acquisition, a transformative d | Sep 9, 2026 |
| SRXH | 8-K | neutral | 3/10 | SRX Global Inc. obtained consent from the holders of its Series C convertible preferred stock to implement a stock repur | Sep 9, 2026 |
| CYCU | 8-K | neutral | 4/10 | Cycurion announced approximately $800,000 in annual contract spend from new commercial and public-health engagements, in | Sep 9, 2026 |
| AGNT | 8-K | neutral | 4/10 | AGNT entered into a stock purchase agreement to repurchase 8,693,290 shares from a trust whose beneficiaries are adult f | Sep 9, 2026 |
| CFTR-PA | 8-K | neutral | 2/10 | Cantor Fitzgerald Income Trust declared its August 2026 monthly distribution for all common share classes and operating | Sep 9, 2026 |
| NTIC | 8-K | neutral | 3/10 | NTIC announced a planned CEO succession: Gautam Ramdas was promoted from VP of Zerust Integrity Solutions to President a | Sep 9, 2026 |
| VNOM | 8-K | neutral | 4/10 | Viper Energy completed its previously announced '2026 Drop Down' acquisition of mineral and royalty interests from Diamo | Sep 9, 2026 |
| SNNF | 8-K | neutral | 2/10 | Board member Kimberly A. Boynton resigned effective September 4, 2026, to pursue other interests, with no disagreement c | Sep 9, 2026 |
| KROS | 8-K | neutral | 4/10 | Keros Therapeutics announced a $5 million share repurchase authorization following a $20 million development milestone p | Sep 9, 2026 |
| INBX | 8-K | bullish | 7/10 | Inhibrx reported Phase 2 data for INBRX-106 in 1L HNSCC, showing a 48.3% cORR vs 26.5% for pembrolizumab alone, with a m | Sep 9, 2026 |